sur NOVACYT (EPA:ALNOV)
Novacyt announces its preliminary results for 2025
Novacyt SA has released its preliminary unaudited results for fiscal year 2025, with figures in line with market expectations. Statutory revenue reached approximately £20 million, representing a 4% increase year-over-year. This growth was driven by strong development in the instrumentation sector, particularly with the LightBench® Discover instrument, and solid performance of NIPT technologies in the clinical sector.
The APAC region contributed significantly to this growth, with a 10% increase in revenue. Despite a slight decline in the RUO segment, the company maintained a strong cash position of £19.2 million without resorting to debt. Novacyt is counting on a promising project pipeline to continue this momentum into 2026.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NOVACYT